Logo

MacroGenics Signs a License Agreement with Zai Lab to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Share this

MacroGenics Signs a License Agreement with Zai Lab to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Shots:

  • MacroGenics receives initial consideration of $55M- including ~$25M up front- $30M as an equity investment in common stock at $31.30/ share & is eligible to receive ~$1.4B as a milestone for 4 programs along with royalties in Zai Lab’s territories
  • Zai lab gets rights to obtain DART & TRIDENT platforms to expand oncology portfolio & lead research program for solid tumors
  • Zai Lab also holds exclusive global licenses to develop- manufacture & commercialize 2 additional molecules. Each company will contribute IP to produce either CD3 or CD47 bispecific Abs. For the lead molecule- Zai Lab receives an option to convert the regional arrangement into a global 50/50 profit share

Ref: Globe Newswire | Image: Sign Builder Illustrated

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions